- [Resource Hub](/)
- [Resource](/?resource-type=poster#library)
- Development of a multi-parameter immunofluorescence assay for identification of circulating tumor cells with epithelial-mesenchymal phenotype

# Development of a multi-parameter immunofluorescence assay for identification of circulating tumor cells with epithelial-mesenchymal phenotype

Circulating tumor cells entering epithelial-mesenchymal transition can lose the surface epithelial markers that capture-based methods depend on; this AACR 2018 poster reports a 5-parameter immunofluorescence assay that identifies CTCs without surface-marker capture and applies it to 5 prostate and 3 breast cancer patients.

Presented by RareCyte and the University of Washington.

Read or download to see:

- A 5-parameter immunofluorescence assay tells epithelial CTCs apart from those carrying mesenchymal markers. Sytox orange stains nuclei, a cytokeratin and EpCAM cocktail marks epithelial cells, vimentin marks mesenchymal differentiation, a CD45, CD11b and CD105 cocktail excludes white blood cells, and EGFR is read as an investigational biomarker; cells are spread onto slides with AccuCyte and imaged on CyteFinder rather than captured on their surface markers.

- In 5 prostate and 3 breast cancer patients, CTC counts ranged from 1 to 164 per sample. Epithelial CTCs averaged 64% of the CTCs found in a patient and epithelial-mesenchymal CTCs 36%, each spanning the full 0 to 100% range, and EGFR-positive cells appeared in both classes; assay specificity was established first against COLO 205 and SKBR-3, which stayed vimentin-negative, and MDA-MB-231 and A549, which stained vimentin-positive.

- Single-cell sequencing confirmed that the epithelial-mesenchymal cells were malignant. In a prostate cancer patient whose tumor carried a TP53 G244S mutation, individual cells retrieved with the CytePicker module were whole-genome amplified and sequenced: the mutation appeared in 2 of 2 epithelial CTCs and 6 of 7 epithelial-mesenchymal CTCs, and in 0 of 6 control white blood cells.

[Download poster](https://cdn.sanity.io/files/s3p6uqps/production/b23c054f8b9844ff2c4ff6620e043bfe8684dd65.pdf)

Your browser doesn’t support embedded PDFs.
[Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/b23c054f8b9844ff2c4ff6620e043bfe8684dd65.pdf) to view it.

[Back to all resources](/#library)
## Related resources
[Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) CyteFinder 2025
### Development of a CTC Based Assay to Characterize MAOA Expression in Metastatic Prostate Cancer
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) [Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) CyteFinder 2024
### New Discoveries in HER2 Detection: A Novel Method of Multimodal Detection of HER2 from a Single Tube of Blood
[Watch Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf) CyteFinder 2024
### Development and analytic validation of an ARv7 / PSMA dual biomarker circulating tumor cell assay
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) CyteFinder 2024
### Development and validation of an assay for the characterization of SSTR2 expression on CTCs from liquid biopsies
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11863877/) CyteFinder The Journal of Liquid Biopsy 2023
### Liquid biopsy kinetics and detection of ERBB2 amplification/HER2-positivity in refractory hepatocellular carcinoma
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11863877/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/b4fe65d132e5579cb5e0a30c9bee5d7ff7f632ab.pdf) CyteFinder 2023
### Novel method for the detection and evaluation of disease biomarkers on white blood cells from liquid biopsies
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/b4fe65d132e5579cb5e0a30c9bee5d7ff7f632ab.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/51dd5a4aee911d671443d768abcfc0b4f83899e8.pdf) CyteFinder 2020
### Validation of a dual-marker ARv7/SYP assay for CTC characterization
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/51dd5a4aee911d671443d768abcfc0b4f83899e8.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/558dd9bd9ab2fa4c95bbc225309f5026bd3b7094.pdf) CyteFinder 2020
### Analytic validation of an assay to detect androgen receptor splice variant ARv7 protein expression on circulating tumor cells from prostate cancer patients
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/558dd9bd9ab2fa4c95bbc225309f5026bd3b7094.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/600f37993438d761629a40034f7702ebe3e46ee3.pdf) CyteFinder 2020
### Investigation of custom biomarkers on circulating tumor cells from clinical samples using RarePlex Developer Kits
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/600f37993438d761629a40034f7702ebe3e46ee3.pdf) [Video](https://www.youtube.com/watch?v=A0dhlNEaohs) CyteFinder 2020
### RarePlex Assays: Design and Analytical Validation
[Watch Video](https://www.youtube.com/watch?v=A0dhlNEaohs) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/d6eac85be7627ae4445c6583acad89fea879177d.pdf) CyteFinder 2020
### Validation of an assay to detect programmed death-ligand 1 (PD-L1) expression on circulating tumor cells
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/d6eac85be7627ae4445c6583acad89fea879177d.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/5962be5f1b2b288f2c069f7bd7b54890839f426a.pdf) CyteFinder 2019
### Custom biomarker investigation of circulating tumor cells using RarePlex® Developer Kits
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/5962be5f1b2b288f2c069f7bd7b54890839f426a.pdf)